No Marshmallows, Just Term Papers
Bharat Book Bureau provides the report; on “Large Cap Pharma US & EU Outlook 2016” This report to improve the productivity by taking different approaches like focusing on selected therapy area and markets, merger and acquisition. https://www.bharatbook.com/healthcare-market-research-reports-420102/large-cap-pharma-us-eu-maximizing-medicine.html
08th April, 2016- Mumbai, India: Bharatbook.com announces a report on “Large Cap Pharma US & EU Outlook 2016” This Report our scientific and business team provides you with their in depth knowledge, experience and perspective on the targeted drug delivery landscape.
Major pharma companies are continue to improve the productivity by taking different approaches like focusing on selected therapy area and markets, merger and acquisition, divestment of non-core brands/segments and consolidation in animal health, vaccines and consumer health care business. Oncology segment has been the key areas of interest for large cap Pharma companies in 2014/2015. The field of immuno-oncology is currently one of the most explosive fields in biotechnology. Bristol-Myers’s with more concentrated effort in Immuno-Oncology has gain the leadership with its Anti-PD-1. Along with Bristol, there's Merck (MRK), Roche (RHHBY), and AstraZeneca (AZN) as well chasing the field. The global estimates of Immuno-oncology drug is expected at >$40 billion in next ten years. Anti-Infective remains a big attraction for large pharm. Merck acquisition of Cubist for $9 billion and Roche’ in-licensing deal for $1billion was the key highlight. Biosimilar development from Large ad Biotech companies are progressing well with many reaching to regulatory space and in lates stage of clinical trials. Biogen Idec streamlined its focus to develop drugs for specialty medicine (Multiple Sclerosis, Inflammatory Bowel Disease), Neurodegeneration (Alzheimer’s disease, Parkinson’s, ALS, Neuro-immunology) and rare diseases (Hemophilia, Spinal Muscular Atrophy and...